Compare Enveric Biosciences Inc (ENVB) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.75 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 24779.4× Enveric Biosciences Inc's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vanguard Emerging Markets Stock Index Fund ETF for 134 Days on average.
| ENVB | VWO | |
|---|---|---|
Market Cap | $6.80M | $168.50B |
Volume | 64,867 | 9,650,999 |
Sector | Health | — |
52-Week High | $10.80 | $61.44 |
52-Week Low | $1.27 | $52.42 |
Typical Hold Time | 14 Days | 134 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
VWO trades at $59.85, down 1.27% with a bearish technical signal. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic weakness creates headwinds. Institutional ownership has increased with Allianz Asset Management growing its stake by 12.6% in Q3 2026, though technical indicators show selling pressure outweighing buying signals.
The outlook remains cautious with emerging markets facing economic divergence. Opportunities exist in semiconductor and technology exposure, but risks include China's property slump and currency volatility. Wall Street sentiment is neutral with the ETF trading near key support levels amid global market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
